Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Mortality following a brain tumour diagnosis in patients with multiple sclerosis.
Neurologic diseases of the central nervous system with pathophysiologically relevant autoantibodies - Perspectives for immunoadsorption.
Immunodetection of oligoclonal bands in serum and CSF of Multiple Sclerosis patients.
Brain intra- and extracellular sodium concentration in multiple sclerosis: a 7 T MRI study.
Inhibition of the TNF Family Cytokine RANKL Prevents Autoimmune Inflammation in the Central Nervous System.
Caregiving in multiple sclerosis.
Role of Microglial M1/M2 Polarization in Relapse and Remission of Psychiatric Disorders and Diseases.
Continuous evolution of magnetic resonance imaging in multiple sclerosis.
Poly(ADP-ribose) polymerase-1 inhibition in brain endothelium protects the blood-brain barrier under physiologic and neuroinflammatory conditions.
[Coexistent depressive and anxiety disorders in epilepsy and multiple sclerosis: a challenge to neuropsychiatric practice.]
Mechanisms and therapeutic implications of the placebo effect in neurological and psychiatric conditions.
Dendritic cells in brain diseases.
Sodium Correction Practice and Clinical Outcomes in Profound Hyponatremia.
Molecular Architecture of Myelinated Nerve Fibers: Leaky Paranodal Junctions and Paranodal Dysmyelination.
Higher Blood Pressure Partially Links Greater Adiposity to Reduced Brain White Matter Integrity.
Increased frequency and severity of restless legs syndrome in patients with neuromyelitis optica spectrum disorder.
Body Mass Index in Multiple Sclerosis: Associations with CSF Neurotransmitter Metabolite Levels.
Is electroconvulsive therapy safe in multiple sclerosis?
[Future issues of the multiple sclerosis treatment from a medical economic viewpoint].
Multiple sclerosis lymphocytes upregulate A2A adenosine receptors which are anti-inflammatory when stimulated.
Validity of The Timed Up and Go as A Measure of Functional Mobility in Persons with Multiple Sclerosis.
Altered molecular expression of TLR-signaling pathways affects the steady-state release of IL-12p70 and IFN-α in patients with relapsing-remitting multiple sclerosis.
Emerging immunopharmacological targets in multiple sclerosis.
The immunoproteasome: a novel drug target for autoimmune diseases.
Peripheral blood non-MAIT CD8+CD161hi cells are decreased in relapsing-remitting multiple sclerosis patients treated with interferon beta.

Pages